Letrozole

A potent breast-cancer aromatase inhibitor that also circulates in AAS contexts for estrogen suppression.

Letrozole is a non-steroidal, reversible aromatase inhibitor — it binds the enzyme that converts androgens into oestrogens and blocks it, so circulating oestrogens fall. In postmenopausal breast-cancer studies that suppression ran roughly 75% to 95%: substantial, though not uniformly complete. A small 12-woman crossover study found it suppresses more completely than anastrozole; that is a pharmacodynamic comparison in postmenopausal women and it does not establish anything about men, steroid users, or which drug is more likely to overshoot.

Oncology-grade evidence for estrogen suppression — near-complete at prescription doses. In men and in non-medical contexts there is no controlled evidence base, and excessive estrogen suppression is a real, documented state.

• STRONG for its approved oncology indications, on large randomised trials in postmenopausal breast cancer.
• OFF-LABEL but guideline-recommended first-line for ovulation induction in selected anovulatory infertility due to PCOS — the US label carries only breast-cancer indications. The pivotal 750-participant trial reported live birth in 27.5% with letrozole against 19.1% with clomiphene. Off-label is not the same as unsupported, and it is also not FDA approval.
• NONE SHOWN for use alongside testosterone or anabolic steroids — no controlled trial exists and the practice is community-derived. Note that controlled male studies do exist in other settings: a 2026 randomised trial in 296 men with spermatogenic failure, and a crossover study in 19 healthy men. Neither validates steroid-adjacent use.
• STRONG in the indicated oncology population for the harms that are actually established: bone mineral density loss, fractures and joint pain, all from randomised trial data and the label. The male "oestrogen crash syndrome" people describe — a bundle of low libido, mood, lipids, sleep and joints — is NOT an established diagnosis and has not been demonstrated as a syndrome; individual effects are real, the packaged version is not.

Oral, with a terminal half-life around two days but a steady state that takes two to six WEEKS to reach — far longer than most people assume, and the reason effects lag decisions considerably. Suppression is reversible once stopped. Male-specific pharmacology is poorly characterised because the drug was not developed for men.

Excessively suppressed estrogen is its own syndrome — low libido, joint pain, mood deterioration, lipid damage, and bone-density loss with time; recovery varies. In men, chronic low estrogen is a documented path to osteoporosis.

• Anyone pregnant — an FDA contraindication — or with a hypersensitivity to it
• Anyone with osteoporosis or bone-density risk factors needs clinician assessment and monitoring rather than an automatic bar
• Anyone using it alongside steroids without a clinician
• Premenopausal women outside a supervised fertility context

• Pregnancy — an FDA CONTRAINDICATION, not a supervision question. The label requires pregnancy testing before oncology treatment, contraception during and for at least three weeks after, and no breastfeeding during or for at least three weeks after. Its fertility use does not change the prohibition on administration during an existing pregnancy.
• Tamoxifen, which lowers letrozole levels through a documented pharmacokinetic interaction.
• Other oestrogen-lowering agents. Note arimistane is not an ordinary supplement: FDA has determined it is not a dietary ingredient and treated products containing it as unapproved new drugs.
• Any use alongside anabolic steroids is unapproved and inadequately studied.

• This is a prescription oncology and fertility drug; use outside those contexts needs a clinician rather than a lab panel. Under supervision, oestradiol is genuinely hard to measure at male concentrations — standard immunoassays can disagree badly with mass spectrometry.
• Bone mineral density — the label says consideration should be given to monitoring it, not that you wait for prolonged use first. Cholesterol monitoring is separately recommended.
• Joint pain, which is common and can cause discontinuation.
• The label also carries post-marketing tendon rupture and tendinitis, hepatitis, anaphylaxis and hypersensitivity reactions, angioedema, toxic epidermal necrolysis and erythema multiforme — rare, with causality caveats, and worth knowing.
• Mood, libido and sleep, which are the signature of oestrogen pushed too low.

Aromatase activity returns once the drug clears and oestrogens climb back. On bone: randomised follow-up found density changes were at least partly reversible after oestrogen recovered — so "it never comes back" overstates it, though recovery is variable, may be incomplete, and established fractures are not undone. Anyone prescribed it for cancer or fertility must not stop without the clinician managing that treatment.

US: prescription-only. Products outside licensed dispensing are unapproved and of uncertain concentration.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Reproductive outcomes after letrozole stimulated versus artificial frozen-thawed embryo transfer cycles in women with PCOS and/or oligo-anovulation: a systematic review and meta-analysis
  Hum Reprod Update, 2025
• Effects of letrozole combined with clomiphene in the treatment of polycystic ovary syndrome: a meta-analysis
  BMC Womens Health, 2025
• Efficacy of letrozole for the treatment of tubal ectopic pregnancy: A meta-analysis
  Eur J Obstet Gynecol Reprod Biol, 2024

• Palbociclib and Letrozole in Advanced Breast CancerN Engl J Med · 2016
• Letrozole: Pharmacology, toxicity and potential therapeutic effectsLife Sci · 2022
• Letrozole for Female InfertilityFront Endocrinol (Lausanne) · 2021
• LetrozoleExpert Opin Drug Metab Toxicol · 2010
• Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndromeCochrane Database Syst Rev · 2022
• Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upBreast Cancer Res Treat · 2019
• Letrozole and Unexplained Infertility: A Contemporary Meta-analysisJ Obstet Gynaecol Can · 2019
• Effects of letrozole combined with clomiphene in the treatment of polycystic ovary syndrome: a meta-analysisBMC Womens Health · 2025
• Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trialJ Med Life · 2023
• Efficacy of letrozole for the treatment of tubal ectopic pregnancy: A meta-analysisEur J Obstet Gynecol Reprod Biol · 2024
• Letrozole pretreatment prior to medical termination of pregnancy: a systematic reviewContraception · 2018
• Letrozole for Ovulation Induction in Women With Polycystic Ovary SyndromeObstet Gynecol Surv · 2026